High levels of RPA2 expression have been associated with adverse disease progression and it may also be a therapeutic potential target for treating colon cancer itself (Givalos et al., 2007), while FOS gene expression has been found to be associated with progression of pancreatic cancer tumors(Guo et al., 2015). Here, RPA2 is linked to familial pancreatic carcinoma.